DUBLIN–(BUSINESS WIRE)–The “Patient
Engagement in R&D: Still a Challenge” report has been added to ResearchAndMarkets.com’s
offering.
The pharmaceutical industry has long considered its primary customers to
be healthcare professionals. This historic approach to patient care has,
in the past few years, been eroded by consumer expectation and online
knowledge sharing among patients – leading to patients becoming ever
more informed, confident, and empowered. Wider attitudinal shifts across
entire healthcare systems are also forcing pharmaceutical companies to
focus more on patients’ needs. Regulations are opening up more patient
involvement; payers and insurers are focusing more on patient
involvement and choice; and even physicians are becoming more
patient-centric. As a result, a new model is emerging – one that places
patients (and their carers, family and personal supporters) at the heart
of the pharmaceutical business. Such a shift is a gradual evolution, but
still represents a significant challenge for the industry – which must
seek to accommodate regulatory demands, shareholder interests, and
broader societal challenges (such as a healthcare system’s ability to
pay for new products).
This is the second of two 2018 supplements that focus on pharma’s
patient engagement in R&D. Both supplements are intended to be used in
conjunction with evidence-based Being Patient-Centric toolkit (published
November 2017), which identified nine key attributes of patient
centricity. Pharma’s success at one of the nine, however – engaging
patients in R&D – has consistently been rated as unimpressive by patient
groups. For example, the 2017 Corporate Reputation of Pharma survey
(results published April 2018) found that 59% of the 1,300 respondent
patient groups thought pharma just “Fair” to “Poor” at engaging
patients/patient groups in product research; and 60% thought the same
for pharma’s record at engaging patients/patient groups in product
development.
Worldwide, only 13% of patient groups responding to 2017 Corporate
Reputation of Pharma survey said that they worked with pharma companies
on clinical research, and only 12% said that they worked with pharma on
clinical trials.
Patient-centric drug R&D: An area in need of improvement
Pharma’s poor performance at engaging patients/patient groups in R&D
prompted PatientView to focus further surveys, research, and analysis on
the subject during 2018. This activity has led to two, new, in-depth
supplements to the original November 2017 Being Patient-Centric toolkit:
1. A US-based supplement (published November 2018); and…
2. A Global-wide supplement (published 11th December 2018).
Key Topics Covered:
Introduction
Key findings
Case study: Barth Syndrome Foundation
Appendix 1: Patient-Centricity in R&D – a revised and updated
toolkit
Appendix 2: Patient-group feedback on how pharma should engage
with patient groups/patients across all R&D functions
Appendix 3: Patient-group feedback on barrier to pharma
engagement with patient groups/patients in R&D
Appendix 4: Patient-group feedback on recommendations on
improving pharma engagement with patient groups/patients in R&D
Appendix 5: Initiatives undertaken by nine pharma companies to
incorporate patients/patient groups into company R&D activities, 2017
For more information about this report visit https://www.researchandmarkets.com/r/uoc5c2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free
Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Healthcare
Services